All lobbying filings

ADVANCED MEDICAL TECHNOLOGY ASSN

ADVANCED MEDICAL TECHNOLOGY ASSN filed a Q3 report for ADVANCED MEDICAL TECHNOLOGY ASSN on October 17, 2025.

Lobbying for ADVANCED MEDICAL TECHNOLOGY ASSN

All filings by ADVANCED MEDICAL TECHNOLOGY ASSN · Everything ADVANCED MEDICAL TECHNOLOGY ASSN has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 17, 2025

Expenses

$860,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 14

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Medicare/Medicaid

Issues related to coverage of telehealth services Issues related to Medicare coverage for digital health technologies - S. 1399 Issues related to S. 1717/H.R. 5343 Ensuring Patient Access to Critical Breakthrough Products Act Issues related to S. 2761/H.R. 5269 Lab Payments and Results Act Issues related to Medicare coverage of FDA's breakthrough devices Issues related to coverage of diabetes devices and supplies Issues related to Home Health Rule

Health Issues

Issues related to Privacy Legislation Issues related to the medical supply chain Issues related to the competitiveness of the medtech industry and the impact of Federal Policies Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to coverage and reimbursement of diagnostic tests Issues related to the use of Artificial Intelligence Issues related to MDUFA Reauthorization Issues related to PFAS Chemical regulation HR 1539 - the Medical Device Electronic Labeling Act Issues related to FDAs third party review program Issues related to the President's Emergency Program for AIDS Relief (PEPFAR) Issues related to National Defense Authorization Act S. 2296/H.R. 3838

Budget/Appropriations

Issues related to appropriations and user fee funding for the Food and Drug Administration

Taxation/Internal Revenue Code

Issues related to R&D Expense Amortization Issues related to small business taxes Issues related to capital investment expensing Issues related to Qualified Small Business Stock

Trade (domestic/foreign)

Tariffs on medical devices United States-Mexico-Canada Agreement (USMCA) Global Trade and EU Tariffs Japan Reimbursement

Small Business

Issues related to the reauthorization of the Small Business Innovation Research (SBIR) program. Issues related to small business taxes. Issues related to Qualified Small Business Stock.

Bills named in this filing 8

S. 1399
Health Tech Investment Act
S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S. 2761
RESULTS Act
H.R. 5269
RESULTS Act
H.R. 1539
Medical Device Electronic Labeling Act
S. 2296
National Defense Authorization Act for Fiscal Year 2026
H.R. 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.